Moderna CEO Bancel Holds 30.38M Shares, Signals Confidence

TL;DR

**Moderna CEO Bancel still owns over 30 million shares, a bullish sign for the stock.**

AI Summary

Stéphane Bancel, CEO of Moderna, Inc., filed an amended SC 13G/A on February 7, 2024, disclosing his beneficial ownership of 30,384,866 shares of Moderna's common stock as of December 31, 2023. This represents a significant stake, indicating his continued confidence and alignment with the company's performance. Investors should note this as a strong signal from an insider, suggesting a belief in Moderna's future prospects.

Why It Matters

This filing shows that Moderna's CEO, Stéphane Bancel, maintains a substantial personal investment in the company, aligning his financial interests directly with those of other shareholders. It's a positive sign for investors, indicating strong insider conviction.

Risk Assessment

Risk Level: low — This filing indicates a stable, significant insider holding, which generally reduces perceived risk due to strong alignment of interests.

Analyst Insight

A smart investor would view Stéphane Bancel's substantial and stable ownership of 30,384,866 shares as a strong indicator of insider confidence, potentially reinforcing a bullish outlook on Moderna's long-term prospects.

Key Numbers

• 30,384,866 — Shares Beneficially Owned (Stéphane Bancel's sole voting and dispositive power over Moderna common stock as of December 31, 2023.)
• December 31, 2023 — Date of Event (The date for which the beneficial ownership was reported.)
• February 7, 2024 — Filing Date (The date the SC 13G/A amendment was filed with the SEC.)

Key Players & Entities

• Stéphane Bancel (person) — Reporting Person, CEO of Moderna, Inc.
• Moderna, Inc. (company) — Subject Company, issuer of the securities
• BOSTON BIOTECH VENTURES, LLC (company) — Group Member
• OCHA LLC (company) — Group Member
• 03 Life Sciences (company) — Organization Name

Forward-Looking Statements

• Stéphane Bancel will maintain a significant ownership stake in Moderna, reflecting continued long-term commitment. (Stéphane Bancel) — high confidence, target: December 31, 2024

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• d752423dsc13ga.htm (SC 13G/A) — 80KB
• 0001193125-24-025972.txt ( ) — 82KB

From the Filing

SC 13G/A 1 d752423dsc13ga.htm SC 13G/A SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934* (Amendment No. 5) Moderna, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 60770K 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 60770K107 1. Names of Reporting Person Stéphane Bancel 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC Use Only 4. Citizenship or Place of Organization France Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 30,384,866 (1) 6. Shared Voting Power 0 7. Sole Dispositive Power 30,384,866 (1) 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 30,384,866 (1) 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 7.8% (2) 12. Type of Reporting Person (See Instructions) IN (1) Consists of (i) 5,429,839 shares of Common Stock held directly by Mr. Bancel, (ii) 9,339,775 shares issuable to Mr. Bancel upon exercise of share options exercisable within 60 days after December 31, 2023, (iii) 6,564,880 shares of Common Stock held by OCHA LLC, and (iv) 9,050,372 shares of Common Stock held by Boston Biotech Ventures, LLC. (2) Percentage ownership is calculated based on (i) 381,794,720 shares of Common Stock outstanding as of December 31, 2023 and (ii) 9,339,775 shares of Common Stock underlying the share options held by Mr. Bancel that are exercisable within 60 days of December 31, 2023 which are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i). (3) Percentage ownership is calculated based on 381,794,720 shares of Common Stock outstanding as of December 31, 2023. CUSIP No. 60770K107 1. Names of Reporting Person OCHA LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 6,564,880 6. Shared Voting Power 0 7. Sole Dispositive Power 6,564,880 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 6,564,880 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 1.7% (3) 12. Type of Reporting Person (See Instructions) OO CUSIP No. 60770K107 1. Names of Reporting Person Boston Biotech Ventures, LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC Use Only 4. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power 9,050,372 6. Shared Voting Power 0 7. Sole Dispositive Power 9,050,372 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 9,050,372 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 11. Percent of Class Represented by Amount in Row (9) 2.4% (3) 12. Type of Reporting Person (See Instructions) OO Item1. (a) Name of Issuer Moderna, Inc. (the Issuer) (b) Address of Issuers Principal Executive Offices 200 Technology Square Cambridge, MA 02139 Item2. (a) Name of Person Filing Stéphane Bancel OCHA LLC Boston Biotech Ventures, LLC (b) Address of Principal Business Office or, if none, Residence c/o Moderna, Inc. 200 Technology Square Cambridge, MA 02139 (c) Citizenship Stéphane Bancel is a citizen of France. Each of OCHA LLC and Boston Biotech Ventures, LLC is a Delaware limited liability company. (d) Title of Class of Securities Common Stock, par value $0.0001 per share (e) CUSIP Number 60770K107 Item3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or deal

View Full Filing

View this SC 13G/A filing on SEC EDGAR